Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Holdings Boosted by DNB Asset Management AS

DNB Asset Management AS grew its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 160,302 shares of the company’s stock after purchasing an additional 14,001 shares during the quarter. DNB Asset Management AS’s holdings in Teva Pharmaceutical Industries were worth $2,605,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. New Covenant Trust Company N.A. bought a new stake in Teva Pharmaceutical Industries in the first quarter worth about $28,000. EntryPoint Capital LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter worth approximately $30,000. Industrial Alliance Investment Management Inc. acquired a new stake in Teva Pharmaceutical Industries during the first quarter valued at approximately $54,000. GAMMA Investing LLC boosted its holdings in Teva Pharmaceutical Industries by 105.7% during the second quarter. GAMMA Investing LLC now owns 3,388 shares of the company’s stock worth $55,000 after buying an additional 1,741 shares in the last quarter. Finally, Psagot Value Holdings Ltd. Israel acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $57,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

TEVA has been the topic of a number of recent research reports. Jefferies Financial Group lifted their target price on Teva Pharmaceutical Industries from $19.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $18.00 to $21.00 and gave the company a “buy” rating in a report on Thursday, May 30th. Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Wednesday, July 10th. Finally, UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.67.

Teva Pharmaceutical Industries Stock Up 1.3 %

Shares of NYSE:TEVA traded up $0.23 during trading on Tuesday, reaching $16.91. 10,189,324 shares of the company traded hands, compared to its average volume of 10,453,374. Teva Pharmaceutical Industries Limited has a 1-year low of $8.06 and a 1-year high of $18.02. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. The firm has a market cap of $19.15 billion, a P/E ratio of -41.41, a price-to-earnings-growth ratio of 1.49 and a beta of 0.90. The firm has a fifty day simple moving average of $16.79 and a 200 day simple moving average of $14.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, May 8th. The company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.03). Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The firm had revenue of $3.82 billion for the quarter, compared to analyst estimates of $3.70 billion. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.35 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 15,500 shares of Teva Pharmaceutical Industries stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $16.80, for a total value of $260,400.00. Following the completion of the sale, the chief accounting officer now owns 17,814 shares of the company’s stock, valued at approximately $299,275.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 519,000 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $17.03, for a total transaction of $8,838,570.00. Following the transaction, the director now owns 981,000 shares in the company, valued at $16,706,430. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Amir Weiss sold 15,500 shares of the company’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total transaction of $260,400.00. Following the sale, the chief accounting officer now directly owns 17,814 shares of the company’s stock, valued at $299,275.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 574,256 shares of company stock valued at $9,776,999. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.